Blood-brain barrier targeting anti-bodies

Details Blood-brain barrier targeting anti-bodies Blood-brain barrier targeting anti-bodies

2011-07-19

2011-07-19

Kolker, Daniel E (Department: 1649)

Drug, bio-affecting and body treating compositions

Immunoglobulin, antiserum, antibody, or antibody fragment,...

Structurally-modified antibody, immunoglobulin, or fragment...

C424S135100, C424S143100, C530S387300

Reexamination Certificate

active

07981417

ABSTRACT:
This invention provides antibodies that bind brain endothelial cell receptors resulting in endocytosis/transcytosis of the receptor and bound ligands. In some embodiments, the ligand comprises the antibody in combination with a pharmaceutically active compound and the antibody directs delivery of the compound across the blood brain barrier (BBB). The invention also provides methods of identifying endothelial cell specific antibodies by panning the library against cultured cell monolayers. The invention further allows for identifying endothelial cell receptors that bind the antibody thereby providing target receptors against which to isolate further cognate ligands and their associated transport systems and by which to identify transcytosis transporters targeted by the antibodies.

REFERENCES:
patent: 7138501 (2006-11-01), Ruben et al.
patent: 2007/0009972 (2007-01-01), Chao et al.
patent: 2005049802 (2005-06-01), None
Verma et al., J Immunol Methods, Jul. 1, 1998, 216(1-2), 165-81.
Feldhaus et al., Nat. Biotechnol. 2003, 21(2),163-70.
Wang et al., Nat. Methods, 2007, 4(2),143-5.
Wu et al., Nat. Biotechnol., Sep. 23, 2005, (9), 1137-46.
Trail et al., Cancer Immunol Immunother, May, 2003, 52(5), 328-37.
Saito et al., Adv Drug Deliv Rev., Feb. 10, 2003;55(2), 199-215.
Wang et al., J Immunol Methods, 2005, 304, 30-42.
Roux et al.. J Cell Physiol, 1994, 159, 101-13.
Martin et al., Analytical Chemistry News & Features, May 1998, 322-327.
Sugano et al., Cancer Research, Dec. 2000, 6942-6949.
Shusta et al., Nat Biotechnol., 2000, 18, 754-9.
Shusta et al., Nat Biotechnol., 1998, 16,773-7.
Shusta el al., J Mol Biol., 1999, 292, 949-56.
Wang et al. 2005 Book of Abstracts, 229th ACS National Meeting, Mar. 13-17, 2005, Abstract No. BIOT-359.
Staddon et al., “P120, A P120-Related Protein (P100), and the Cadherin/Catenin Complex,” Journal of Cell Biology, Rockefeller University Press, New York, US, US, vol. 130, No. 2, Jul. 1995, pp. 369-381.
Dixelius et al., “Endostatin-induced tyrosine kinase signaling through the Shb Adaptor Protein Regulates Endothelial Cell Apoptosis,” Blood, W. B. Saunders Company, Orlando, Fl, US, vol. 95, No. 11, Jun. 1, 2000, pp. 3403-3411.
Novak et al., “A New Low Density Lipoprotein Receptor Homologue with 8 Ligand Binding Repeats in Brain of Chicken and Mouse.” The Journal of Biological Chemistry May 17, 1996, vol. 271, No. 20, pp. 11732-11736.
Yamamoto et al., “The Human LDL Receptor: A Cysteine-Rich Protein with Multiple ALU Sequences in its MRNA,” Cell, Mit Press, Cambridge, MA, US, vol. 391 Nov. 1, 1984, pp. 27-38.
Duffy et al., “Human Blood-Brain Barrier Insulin-Like Growth Factor Receptor,” Metabolism Clinical and Experimental Feb 1988, vol. 37, No. 8, Feb. 1988, pp. 136-140.
Benjamin J Hackel et al., “Production of Soluble and Active Transferrin Receptor-Targeting Single-Chain Antibody Using Saccharomyces Cerevisiae,” Pharmaceutical Research, Kluwer Academic Publishers-Plenum Publishers, NE, vol. 23, No. 4, Mar. 25, 2006, pp. 790-797.
PCT/US2007/070587 Search Report; Jan. 14, 2008.

Affiliated with

Also associated with

Rating

Blood-brain barrier targeting anti-bodies does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Blood-brain barrier targeting anti-bodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Blood-brain barrier targeting anti-bodies will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2683578